The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Open accessAbstract
During carcinogenesis of pancreatic islets in transgenic mice, an angiogenic switch activates the quiescent vasculature. Paradoxically, vascular endothelial growth factor (VEGF) and its receptors are expressed constitutively. Nevertheless, a synthetic inhibitor (SU5416) of VEGF signalling impairs angiogenic switching and tumour growth. Two metalloproteinases, MMP-2/gelatinase-A and MMP-9/gelatinase-B, are upregulated in angiogenic lesions. MMP-9 can render normal islets angiogenic, releasing VEGF. MMP inhibitors reduce angiogenic switching, and tumour number and growth, as does genetic ablation of MMP-9. Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
From Inflammation and cancer (2002) · cites this paper as [26]
In the citing paper
“Furthermore, the actions of MMP-9 both break down the fibrous collagen matrix to make space for new blood vessels and release matrix-bound VEGF (53).”
From The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. (2017) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,162
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,661
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,107
Self-citationYu, Q., & Stamenkovic, I. (2000) · PubMed · Cited by 1,952
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Self-citationYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Cited by
Sorted by citations
Items 901–1,000 of 1,009
Cai, H., Ma, Y., Jiang, L., Mu, Z., Jiang, Z., Chen, X., Wang, Y., Yang, G., & Zhang, Z. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.020 · Cited by 75
Karaplis, A. C. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50105-0 · Cited by 76
Emerging and multifaceted role of neutrophils in lung cancer
Aloe, C. A., Wang, H., Vlahos, R., Irving, L. B., Steinfort, D., & Bozinovski, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-760 · Cited by 74
“This facilitates both the intravasation of cancer cells into the bloodstream and the sequestering of matrix-bound cytokine receptors, adhesion molecules and angiogenic factors, where MMP-9 mediated sequestering of VEGF from the ECM is shown to be a principle driver of the ‘angiogenic switch’, which leads to neovascula…”
BackgroundRole of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration.
Heissig, B., Nishida, C., Tashiro, Y., Sato, Y., Ishihara, M., Ohki, M., Gritli, I., Rosenkvist, J., & Hattori, K. (2010) · PubMed · doi:10.14670/hh-25.765 · Cited by 73
İşeri, Ö. D., Kars, M. D., Arpacı, F., & Gündüz, U. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1048-z · Cited by 73
Lubbe, W. J., Zhou, Z., Fu, W., Zuzga, D. S., Schulz, S., Fridman, R. A., Muschel, R. J., Waldman, S. A., & Pitari, G. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2686 · Cited by 73
Matrix metalloproteinase inhibitors as anticancer agents
Konstantinopoulos, P. A., Karamouzis, M. V., Papatsoris, A., & Papavassiliou, A. G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.007 · Cited by 74
Bruni‐Cardoso, A., Johnson, L. C., Vessella, R. L., Peterson, T. E., & Lynch, C. C. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0445 · Cited by 74
Tsai, P.-H., Cheng, C., Lin, C., Huang, Y.-T., Lee, L.-T., Kandaswami, C. C., Lin, Y.-C., LEE, K. P.-H., Hung, C., Hwang, J.-J., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11234 · Cited by 73
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Werfel, T. A., Wang, S., Jackson, M. A., Kavanaugh, T. E., Joly, M. M., Lee, L., Hicks, D. J., Sanchez, V. M., Ericsson, P. I. G., Kilchrist, K. V., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2388 · Cited by 73
Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
Luttun, A., Autiero, M., Tjwa, M., & Carmeliet, P. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.09.002 · Cited by 75
Milestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 79
“In RIP1-Tag2 mice, VEGFA is expressed in normal and premalignant pancreatic islets before the angiogenic switch, where it is largely sequestered in the ECM and remains inactive 43 .”
InfluentialSelf-citationGamble, J. R., Xia, P., Hahn, C. N., Drew, J., Drogemuller, C., Brown, D., & Vadas, M. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.21682 · Cited by 72
The Role of Matrix Metalloproteinases in Stromal/Epithelial Interactions in the Gut
Sengupta, N., & MacDonald, T. T. (2007) · Physiology · doi:10.1152/physiol.00027.2007 · Cited by 72
Activation of the erythropoietin receptor in human skeletal muscle
Rundqvist, H., Rullman, E., Sundberg, C. J., Fischer, H., Eisleitner, K., Ståhlberg, M., Sundblad, P., Jansson, E., & Gustafsson, T. P. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0342 · Cited by 71
McGuane, J. T., Danielson, L. A., Debrah, J. E., Rubin, J. P., Novak, J., & Conrad, K. P. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.165027 · Cited by 72
Hojilla, C. V., Wood, G. A., & Khokha, R. (2008) · Breast Cancer Research · doi:10.1186/bcr1980 · Cited by 72
Detection of MMP activity in living cells by a genetically encoded surface-displayed FRET sensor
Yang, J., Zhang, Z., Lin, J., Lu, J., Liu, B., Zeng, S., & Luo, Q. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.002 · Cited by 75
Gannon, G., Mandriota, S. J., Cui, L., Baetens, D., Pepper, M. S., & Christofori, G. (2002) · PubMed · Cited by 70
Verma, D., Zanetti, C., Godavarthy, P. S., Kumar, R., Minciacchi, V. R., Pfeiffer, J., Metzler, M., Lefort, S., Maguer‐Satta, V., Nicolini, F. E., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0674-7 · Cited by 71
Gupta, A., Zhou, C. Q., & Chellaiah, M. A. (2013) · Cancers · doi:10.3390/cancers5020617 · Cited by 71
Sun, W. H., Sun, Y. L., Fang, R.-N., Shao, Y., Xu, H. C., Xue, Q. P., Ding, G.-X., & Cheng, Y. L. (2005) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi196 · Cited by 71
FGF-2 Release from the Lens Capsule by MMP-2 Maintains Lens Epithelial Cell Viability
Tholozan, F. M., Gribbon, C., Li, Z., Goldberg, M. W., Prescott, A. R., McKie, N., & Quinlan, R. A. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0416 · Cited by 71
Javadian, M., Gharibi, T., Shekari, N., Abdollahpour‐Alitappeh, M., Mohammadi, A., Hossieni, A., Mohammadi, H., & Kazemi, T. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27445 · Cited by 71
“…VIII, and perlecan by MMP‐9, enhances the bioavailability of two major proangiogenic factors including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) respectively (Bergers et al., 2000; Iozzo, Zoeller, & Nyström, 2009; Whitelock et al., 1996; Xu et al., 2001).”
BackgroundHarvey, S. R., Hurd, T. C., Markus, G., Martinick, M., Penetrante, R. M., Tan, D., Venkataraman, P., DeSouza, N., Sait, S. N. J., Driscoll, D. L., et al. (2003) · PubMed · Cited by 71
Trappen, P. O. V., Ryan, A., Carroll, M., Lecœur, C., Goff, L. K., Gyselman, V. G., Young, B. D., Lowe, D. G., Pepper, M. S., Shepherd, J. H., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600471 · Cited by 72
Stadler, M., Walter, S., Walzl, A., Kramer, N., Unger, C., Scherzer, M., Unterleuthner, D., Hengstschläger, M., Krupitza, G., & Dolznig, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.007 · Cited by 73
Effect of Korean Red Ginseng on metabolic syndrome
Yoon, S. J., Kim, S. K., Lee, N. Y., Choi, Y. R., Kim, H. S., Gupta, H., Youn, G. S., Sung, H., Shin, M. J., & Suk, K. T. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.11.002 · Cited by 71
“What’s more, MMP-2 and MMP-9 was found to indirectly enhance angiogenesis [71,72], which suggests that obesity is mediated by synergistic action between angiogenesis and MMPs.”
BackgroundNeutrophil-derived granule cargoes: paving the way for tumor growth and progression
Rawat, K., Syeda, S., & Shrivastava, A. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09951-1 · Cited by 75
Proteases and the Biology of Glioma Invasion
Binder, D. K., & Berger, M. S. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1014566604005 · Cited by 70
Inhibitory Effect of Green Tea Polyphenols on Membrane-Type 1 Matrix Metalloproteinase, MT1-MMP1)
Oku, N., Matsukawa, M., Yamakawa, S., Asai, T., Yahara, S., Hashimoto, F., & Akizawa, T. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.1235 · Cited by 70
Yang, P., Yuan, W., He, J., Wang, J., Yu, L., Jin, X., Hu, Y., Liao, M., Chen, Z., & Zhang, Y. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00563.x · Cited by 70
Vempati, P., Gabhann, F. M., & Popel, A. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011860 · Cited by 70
Arnold, S. A., Mira, E., Muneer, S., Korpanty, G. J., Beck, A. W., Holloway, S. E., Mañes, S., & Brekken, R. A. (2008) · Experimental Biology and Medicine · doi:10.3181/0801-rm-12 · Cited by 70
Self-citationMatrix Metalloproteinases Play an Active Role in Wnt1-Induced Mammary Tumorigenesis
Blavier, L., Lazaryev, A., Dorey, F. J., Shackleford, G. M., & DeClerck, Y. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2919 · Cited by 67
Langlois, B., Saupe, F., Rupp, T., Arnold, C., van der Heyden, M., Orend, G., & Hussenet, T. (2014) · Oncotarget · doi:10.18632/oncotarget.2470 · Cited by 76
“MMP-9 and MMP-2 represent candidate drivers of the transition since both are induced during the RIP1-Tag2 angiogenic switch and MMP9 in particular exerts a crucial role [6] and both MMPs are able to activate latent TGF-β [38].”
BackgroundAntiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities
Wong, E. T., & Brem, S. S. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0039 · Cited by 69
The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome.
Seki, Y., Suico, M. A., Uto, A., Hisatsune, A., Shuto, T., Isohama, Y., & Kai, H. (2002) · PubMed · Cited by 70
Emonard, H., Bellon, G., de Diesbach, P., Mettlen, M., Hornebeck, W., & Courtoy, P. J. (2004) · Biochimie · doi:10.1016/j.biochi.2004.11.013 · Cited by 69
Momeny, M., Khorramizadeh, M. R., Ghaffari, S. H., Yousefi, M., Yekaninejad, M. S., Esmaeili, R., Jahanshiri, Z., & Noori–Daloii, M. R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.011 · Cited by 72
Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension
Safdar, Z., Tameez, E., Chan, W., Arya, B., Ge, Y., Deswal, A. M., Bozkurt, B., Frost, A., & Entman, M. L. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.03.013 · Cited by 69
Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
KIM, W., & KAELINJR, W. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.001 · Cited by 73
Integrin α3β1 as a breast cancer target
Subbaram, S., & DiPersio, C. M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.609557 · Cited by 72
Tumor Environment Dictates Medulloblastoma Cancer Stem Cell Expression and Invasive Phenotype
Annabi, B., Rojas‐Sutterlin, S., Laflamme, C., Lachambre, M., Rolland, Y., Sartelet, H., & Béliveau, R. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2184 · Cited by 69
Earlier Onset of Tumoral Angiogenesis in Matrix Metalloproteinase-19–Deficient Mice
Jost, M., Folgueras, A. R., Frérart, F., Pendás, A. M., Blacher, S., Houard, X., Berndt, S., Munaut, C., Cataldo, D. D., Álvarez, J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4315 · Cited by 69
Nie, W., Yu, T., Sang, Y., & Gao, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.048 · Cited by 72
Architecture in 3D cell culture: An essential feature for in vitro toxicology
Lelièvre, S. A., Kwok, T., & Chittiboyina, S. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.03.012 · Cited by 72
“Earlier demonstration that a matrix from cancer can lead to carcinogenesis (Bergers et al., 2000; Bourboulia et al., 2010; Buchheit et al., 2012) is a AC CE PT ED M AN US CR IP T 1976, experiments with hepatocytes in floating collagen cultures had revealed that under these conditions the cells…”
Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis
Mazzone, M., & Bergers, G. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114721 · Cited by 70
“As described above, neutrophils could secrete MMP9 to liberate extracellular matrix–sequestered VEGF in dysplastic pancreatic islets of Rip1Tag2 mice that was sufficient to induce the angiogenic switch (42, 54), whereas pharmacological neutrophil depletion impaired the angiogenic switch in these pancreatic islet lesio…”
BackgroundSelf-citationMatrix metalloproteinases and angiogenesis
Jackson, C. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200205000-00005 · Cited by 69
Bone Angiogenesis and Vascular Niche Remodeling in Stress, Aging, and Diseases
Stücker, S., Chen, J., Watt, F. E., & Kusumbe, A. P. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602269 · Cited by 71
“, 2011a) and stimulate tumor angiogenesis via releasing ECM-bound VEGF (Bergers et al., 2000).”
BackgroundPinkas, J., & Leder, P. (2002) · PubMed · Cited by 68
Chronic and non-healing wounds: The story of vascular endothelial growth factor
Zhou, K., Ma, Y., & Brogan, M. S. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.06.017 · Cited by 69
“With tissue or skin injury, VEGFR-1 induces the migration of monocytes/macrophages, recruits hematopoietic stem cells, and inducts the release of matrix metalloproteinases (MMPs) [11–13].”
BackgroundOncogenic HRAS suppresses clusterin expression through promoter hypermethylation
Lund, P., Weißhaupt, K., Mikeska, T., Jammas, D., Chen, X. '., Kuban, R., Ungethüm, U., Krapfenbauer, U., Herzel, H.-P., Schäfer, R., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209502 · Cited by 68
Halade, G. V., Ma, Y., Ramirez, T. A., Zhang, J., Dai, Q., Hensler, J. G., Lopez, E. F., Ghasemi, O., Jin, Y.-F., & Lindsey, M. L. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00224.2013 · Cited by 68
24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development
Soncini, M., Corna, G., Moresco, M. A., Coltella, N., Restuccia, U., Maggioni, D., Raccosta, L., Lin, C., Invernizzi, F., Crocchiolo, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613332113 · Cited by 69
“MMP9 myeloid cells sustain the angiogenic switch in this tumor model (18).”
BackgroundHattori, S., Fujisaki, H., Kiriyama, T., Yokoyama, T., & Irie, S. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5479 · Cited by 68
Younes, M. N., Park, Y. W., Yazici, Y. D., Gu, M., Santillan, A. A., Nong, X., Kim, S., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0228 · Cited by 68
The Three A’s in Asthma – Airway Smooth Muscle, Airway Remodeling & Angiogenesis
Keglowich, L., & Borger, P. (2015) · The Open Respiratory Medicine Journal · doi:10.2174/1874306401509010070 · Cited by 71
“VEGF for instance binds to the ECM through heparan sulphate proteoglycans and is released upon matrix degradation processes [35, 36].”
Aparna, M., Rao, L., Kunhikatta, V., & Radhakrishnan, R. A. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12245 · Cited by 67
Yao, J. S., Shen, F., Young, W. L., & Yang, G. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.008 · Cited by 67
Cretu, A., & Brooks, P. C. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21222 · Cited by 67
Ngo, M. T., & Harley, B. A. C. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700687 · Cited by 64
Yan, C., Wang, H., Toh, Y., & Boyd, D. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210369200 · Cited by 67
Francisco, I. F. S., DeWolf, W. C., Peehl, D. M., & Olumi, A. F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20388 · Cited by 68
VEGF Gene Delivery for Treatment of Ischemic Cardiovascular Disease
Koransky, M. L., Robbins, R. C., & Blau, H. M. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00158-x · Cited by 67
Zeng, H., Datta, K., Neid, M., Li, J., Parangi, S., & Mukhopadhyay, D. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00107-4 · Cited by 67
Winding, B., NicAmhlaoibh, R., Misander, H., Høegh-Andersen, P., Andersen, T. L., Holst‐Hansen, C., Heegaard, A., Foged, N. T., Brünner, N., & Delaissé, J. (2002) · PubMed · Cited by 67
Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy
Zilio, S., & Serafini, P. (2016) · Vaccines · doi:10.3390/vaccines4030031 · Cited by 70
“Pro-MMP9 facilitates VEGF bioavailability [149], and its interaction with VEGFR.”
BackgroundProgress in the treatment of solid tumors with apatinib: a systematic review
Zhao, D., Hou, H., & Zhang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172305 · Cited by 66
“22 Meanwhile, VEGFR-2 expression is also upregulated in tumor vasculature compared to the normal vascular system.”
Park, K. C., Dharmasivam, M., & Richardson, D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186805 · Cited by 70
Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer
Wagner, N., & Wagner, K. (2022) · Cells · doi:10.3390/cells11152432 · Cited by 69
Guo, R., Zhong, C., Shi, M., Zhang, C., Wei, W., Zhang, Y.-Q., & Li, J. Q. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0097-5 · Cited by 66
Bone Marrow Microenvironment and Tumor Progression
Chantrain, C. F., Féron, O., Marbaix, É., & DeClerck, Y. A. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0010-7 · Cited by 66
Transcriptional anti-angiogenesis therapy of human pancreatic cancer
Xie, K., WEI, D., & Huang, S. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.01.002 · Cited by 66
Kaimal, R., Aljumaily, R. M., Tressel, S. L., Pradhan, R. V., Covic, L., Kuliopulos, A., Zarwan, C., Kim, Y. B., Sharifi, S., & Agarwal, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1426 · Cited by 66
Hua, C., Zhao, G., Feng, Y., Yuan, H., Song, H., & Bie, L. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3724 · Cited by 70
Grünwald, B. T., Vandooren, J., Locatelli, E., Fiten, P., Opdenakker, G., Proost, P., Krüger, A., Lellouche, J., Israel, L. L., Shenkman, L., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.016 · Cited by 66
Modulation of angiogenesis with siRNA inhibitors for novel therapeutics
Lu, P. Y., Xie, F. Y., & Woodle, M. C. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.01.005 · Cited by 67
A Critical Role for the Inflammatory Response in a Mouse Model of Preneoplastic Progression
Schwertfeger, K. L., Xian, W., Kaplan, A. M., Burnett, S. H., Cohen, D. A., & Rosen, J. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3781 · Cited by 66
Jiang, Y., & Muschel, R. J. (2002) · PubMed · Cited by 66
Somiari, S., Shriver, C. D., Heckman, C., Olsen, C. H., Hu, H., Jordan, R. M., Arciero, C. A., Russell, S., Garguilo, G., Hooke, J. A., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.03.003 · Cited by 66
The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Aloizou, A.-M., Pateraki, G., Siokas, V., Mentis, A.-F. A., Liampas, I., Lazopoulos, G., Kovatsi, L., Mitsias, P. D., Bogdanos, D. P., Paterakis, K., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.001 · Cited by 69
“MMPs break down components of the extracellular matrix, participating in glioma cell motility and tissue invasion [85,86], and triggering angiogenesis [87];they have further been found overexpressed in glioma [78].”
BackgroundThe relationship between previous pulmonary tuberculosis and risk of lung cancer in the future
Qin, Y., Chen, Y., Chen, J., Xu, K., Xu, F., & Shi, J. (2022) · Infectious Agents and Cancer · doi:10.1186/s13027-022-00434-2 · Cited by 65
Satpathy, M., Shao, M., Emerson, R. E., Donner, D. B., & Matei, D. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808331200 · Cited by 69
Parmo‐Cabañas, M., Molina‐Ortiz, I., Matı́as-Román, S., García‐Bernal, D., Carvajal‐Vergara, X., Valle, I., Pandiella, A., Arroyo, A. G., & Teixidó, J. (2005) · The Journal of Pathology · doi:10.1002/path.1876 · Cited by 65
Vempati, P., Popel, A. S., & Gabhann, F. M. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-59 · Cited by 65
Peptide-Based Selective Inhibitors of Matrix Metalloproteinase-Mediated Activities
Ndinguri, M. W., Bhowmick, M., Tokmina‐Roszyk, D., Robichaud, T. K., & Fields, G. B. (2012) · Molecules · doi:10.3390/molecules171214230 · Cited by 65
Vasculogenic Cytokines in Wound Healing
Wong, V., & Crawford, J. D. (2013) · BioMed Research International · doi:10.1155/2013/190486 · Cited by 67
Aplin, A. C., Zhu, W. H., Fogel, E., & Nicosia, R. F. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00019.2009 · Cited by 66
Bu, P., Gao, L., Zhuang, J., Feng, J., Yang, D., & Yan, X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0260 · Cited by 65
Huang, J., Chen, K., Chen, J., Gong, W., Dunlop, N. M., Howard, O. M. Z., Gao, Y., Xw, B., & Wang, J. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605591 · Cited by 65
Markedly Decreased Blood Perfusion of Pancreatic Islets Transplanted Intraportally Into the Liver
Henriksnäs, J., Lau, J., Zang, G., Berggren, P., Köhler, M. G., & Carlsson, P. (2012) · Diabetes · doi:10.2337/db10-0895 · Cited by 65
Singh, K., Sinha, M., Pal, D., Tabasum, S., Gnyawali, S. C., Khona, D. K., Sarkar, S., Mohanty, S. K., Gonzalez, F. S., Khanna, S., et al. (2019) · Diabetes · doi:10.2337/db19-0202 · Cited by 65
“In addition, ZEB1 deficiency compromised the expression of MMP-9 known to act upstream of VEGF in the angiogenic pathway (59).”
BackgroundSimizu, S., Takagi, S., Tamura, Y., & Osada, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4446 · Cited by 65
Mammary Gland Reprogramming: Metalloproteinases Couple Form with FunctionPreprint
Khokha, R., & Werb, Z. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004333 · Cited by 73
Self-citationPiwócka, O., Piotrowski, I., Suchorska, W. M., & Kulcenty, K. I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1343523 · Cited by 69
A mechanistic study of colon cancer growth promoted by cigarette smoke extract
Ye, Y. N., Wu, W. K. K., Shin, V. Y., & Cho, C. H. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.07.009 · Cited by 64
Matrix metalloproteinase-induced genomic instability
Radisky, D. C., & Bissell, M. J. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.011 · Cited by 66
Critical role of microenvironmental factors in angiogenesis
Banfi, A., von Degenfeld, G., & Blau, H. M. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0011-7 · Cited by 64
Lan, Y.-Y., Hsiao, J., Chang, K., Chang, J. S.-M., Chen, C.-W., Lai, H.-C., Wu, S.-Y., Yeh, T.-H., Chang, F.-H., Lin, W., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00174-12 · Cited by 64
Metadata
- Authors
- Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Hope Heart Institute (US)
- Kyoto University (JP)
- Harold C. Simmons Comprehensive Cancer Center (US)
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Hanahan, Douglas
- Venue
- Nature Cell Biology
- Published
- 2000-09-20
- Volume
- 2
- Issue
- 10
- Pages
- 737-744
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC2852586
- OpenAlex
- W1574172480
- Cited by
- 2,797
- References
- 45
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 76 · 2023: 74 · 2022: 96 · 2021: 90 · 2020: 92 · 2019: 88 · 2018: 82 · 2017: 107 · 2016: 110 · 2015: 98 · 2014: 133 · 2013: 140 · 2012: 137
- FWCI
- 36.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- MMP-9, angiogenic switch, vascular endothelial growth factor, VEGF signaling, MMP-2, urokinase, tumor angiogenesis, tumor growth, matrix metalloproteinase inhibitors, SU5416, transgenic mice
- MeSH terms
- Acetamides, Animals, Cell Transformation, Neoplastic, Genes, Switch, Islets of Langerhans, Lymphokines, Mice, Transgenic, Neovascularization, Pathologic, Pancreatic Neoplasms, Tissue Distribution, Signal Transduction, Endothelial Growth Factors, Receptors, Growth Factor, Matrix Metalloproteinase 9, Receptor Protein-Tyrosine Kinases, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
